A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients

A Randomized, Placebo/Active Controlled, Single/Multiple Dosing, Dose Escalation Clinical Phase 1a/b Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients

This study aims to evaluate the safety, tolerability and pharmacokinetic properties of IN-A002 Ointment in healthy adult male volunteers and mild to moderate atopic dermatitis patients

Study Overview

• Status: Not yet recruiting
• Conditions: Mild to Moderate Atopic Dermatitis
• Intervention / Treatment: Drug: IN-A002 Ointment 0.3% or IN-A002 Placebo Ointment; Drug: IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment; Drug: IN-A002 Ointment 1% or IN-A002 Placebo Ointment; Drug: IN-A002 Ointment 3% or IN-A002 Placebo Ointment; Drug: IN-A002 Ointment 5% or IN-A002 Placebo Ointment; Drug: IN-A002 Ointment 1%; Drug: IN-A002 Ointment 3%; Drug: Elidel Cream 1% (pimecrolimus)

Detailed Description

Part A: Phase 1a Study

• Primary objective

  - To evaluate the safety and tolerability after single/multiple dosing of topical IN-A002 Ointment in healthy adult male volunteers.

• Secondary objective - To evaluate the pharmacokinetic (PK) profile after single/multiple dosing of topical IN-A002 Ointment in healthy adult male volunteers

Part B: Phase 1b Study

• Primary objective

  - To evaluate the safety and tolerability after multiple dosing of topical IN-A002 Ointment in patients with mild to moderate atopic dermatitis.

• Secondary objectives

  • To evaluate the PK profile after multiple dosing of topical IN-A002 Ointment in patients with mild to moderate atopic dermatitis.
  • To evaluate the efficacy after multiple dosing of topical IN-A002 Ointment in patients with mild to moderate atopic dermatitis.

• Study Type: Interventional
• Enrollment (Anticipated): 80
• Phase: Phase 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

[Part A] 1a study

Inclusion Criteria:

• Healthy adult male volunteers aged 19 years or older when the informed consent is obtained.
• Those whose body weight is above 50.0 kg, with body mass index (BMI) BMI ≥ 18.0 and ≤ 30.0 kg/m2 at screening.
• Those who have no skin disorder or damage (including scars, tattoos, heavy freckle) that may affect the absorption of investigational product, or have no heavy hair in the drug application area.
• Those who have no congenital or chronic disease, or pathological symptoms or findings in the result of medical examination.
• Those who are judged eligible for this study upon judgment of the investigator in screening tests established depending on the characteristics of investigational product (examinations by interview, clinical laboratory test, vital signs, physical examinations, 12-lead electrocardiogram (ECG)).
• Those who have fully understood this clinical trial via detailed explanation, were willing to voluntarily participate in this study, and agreed to give written informed consent prior to the screening procedure.

Exclusion Criteria:

• Subjects who have the following prior/current history in addition to experience or history of clinically significant hepatic, renal, neurological, psychiatric, respiratory, endocrine, hematological, malignancy, urogenital, cardiovascular, digestive, or musculoskeletal disease:

  ① Atopic dermatitis ② Psoriasis ③ Eczema ④ Contact dermatitis ⑤Thrombocytopenia ⑥ Anemia ⑦ Neutropenia ⑧ Latent or active tuberculosis

• Subjects who have history of hypersensitivity (e.g., anaphylactic reaction or angioedema) to the drugs, including Janus kinase inhibitors and excipients, and other drugs (aspirin, penicillin antibiotics, macrolide antibiotics), or subjects who have history of clinically significant hypersensitivity.
• Suspected acute viral or bacterial infection within 2 weeks prior to the expected initial application date, or fever (body temperature in the tympanic membrane ≥ 38.0ºC) at the time of screening.

• The following clinically significant findings on 12-lead ECG at screening:

  • QTc > 450 ms
  • PR interval > 200 ms
  • QRS duration > 120 ms

• Any of the following abnormalities in clinical laboratory tests at screening:

  • Blood count (platelet or ANC level < 0.5 x lower limit of normal);
  • Liver function test (AST, ALT, ALP, γ-GTP, or total bilirubin level is ≥ 2 x upper limit of normal);
  • Serum creatinine level that is outside the reference range, or an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2 as determined by the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) Equation;
  • Positive anti-HCV, HBs Ag, HIV Ag/Ab, Syphilis-RPR, or IGRA test.
• Subjects who received live vaccines within 3 months prior to the expected initial application date, or subjects who have a plan to receive live vaccines over a period from the informed consent to post-study visit (PSV).
• Subjects who have history of drug abuse, or who have a positive urine test for drugs of abuse.

• Subjects who have shown the following vital signs at screening when measured after at least 3-min rest:

  • Sitting systolic blood pressure ≥ 150 mmHg or ≤ 90 mmHg.
  • Sitting diastolic blood pressure ≥ 100 mmHg or ≤ 60 mmHg.
  • Sitting pulse rate ≤ 40 bpm or ≥ 100 bpm.
• Subjects who cannot continuously abstain from sunbath or artificial suntan over a period from 2 weeks prior to the expected initial application date to PSV.
• Subjects who have taken prescription drugs or oriental medicines that may affect the characteristics of investigational product within 2 weeks prior to the expected initial application date, or subjects who have taken OTC drugs or vitamin preparations within 10 days prior to the expected initial application date, or subjects who are expected to take the above drugs over a period from the informed consent to PSV (however, if the drug is judged not to affect the evaluation of investigational product by the investigator, the subject may participate in the clinical trial.).
• Subjects who have taken any drugs known to significantly induce (e.g., barbiturates) or inhibit drug-metabolizing enzymes within 1 month prior to the expected initial application date.
• Subjects who have participated in other clinical trials within 6 months prior to the expected initial application date (however, for the completion date of other clinical trials, the next date is calculated as 1 day on the basis of the last application date.).
• Subjects who have donated whole blood within 2 months prior to the expected initial application date or apheresis within 1 month, or received blood transfusion within 1 month prior to the expected initial application date, or subjects who cannot continuously abstain from blood donation over a period from the informed consent to PSV.

• Subjects who have history of regular alcohol consumption exceeding 21 units/week (1 unit = 10 g = 12.5 mL of pure alcohol) within 6 months prior to the expected initial application date, or subjects who cannot continuously abstain from alcohol consumption over a period from the informed consent to PSV.

  ☞The amount of alcohol (g) = alcohol consumption (mL) x alcohol content (%) x 0.8

• Subjects who have history of average use of 10 cigarettes daily within 3 months prior to the expected initial application date, and subjects who cannot cease smoking over a period from 24 hours prior to the expected initial application date to the last blood sampling point.
• Subjects who consumed grapefruit-containing food from 48 hours prior to the expected initial application date to PSV, or subjects who cannot avoid taking grapefruit-containing food during this period.
• Subjects who consumed caffeine-containing food (coffee, green tea, black tea, carbonated beverage, coffee-flavored milk, tonics, etc.) from 24 hours prior to the expected initial application date to the last blood sampling point, or subjects who cannot avoid drinking caffeine-containing food during this period.
• Subjects participating in regular strenuous exercise greater than daily physical activity from 48 hours prior to the expected initial application date to PSV, or subjects who cannot abstain from strenuous exercise during this period.
• Subjects or spouses (or partners) who have a plan for pregnancy or although unplanned pregnancy, are unable to use a highly effective method of contraception (e.g., use/implant of hormonal contraceptive or correctly placed intrauterine device, sterilization surgery (vasectomy, tubal ligation, etc.), barrier method (spermicide and condom, a concomitant use of contraceptive diaphragm, vaginal sponge or cervical cap)), over a period from the informed consent to 90 days after the last dose of investigational product.
• Subjects who are judged ineligible for the clinical study by the investigator due to reasons other than the above inclusion/exclusion criteria.

[Part B] 1b Study

Inclusion Criteria:

• Adult male volunteers aged ≥ 19 years and ≤ 65 years when the informed consent is obtained.
• BMI ≥ 18.0 and ≤ 30.0 kg/m2 at screening.
• Subjects who have fully understood this clinical trial via detailed explanation, were willing to voluntarily participate in this study, and agreed to give written informed consent prior to the screening procedure.
• Confirmed diagnosis of AD according the criteria of Hanifin and Rajka (1980).
• AD lesions that can be applied by investigational product, with a minimum of 5% to a maximum of 30% BSA involvement at screening.
• AD diagnosed by EASI score of mild (EASI < 16) or moderate (16 ≤ EASI < 23) at screening.
• Blood vessels whose blood sample collection may be available for PK analysis.
• Subjects who are judged eligible for this study upon judgment of the investigator in screening tests established depending on the characteristics of investigational product (examinations by interview, clinical laboratory test, vital signs, physical examinations, 12-lead ECG).

Exclusion Criteria:

• Subjects who have the following prior/current history in addition to evidence or history of clinically significant skin disorders other than AD (however, the patients with skin disorders that may not affect the AD treatment), hepatic, renal, neurological, psychiatric, respiratory, endocrine, hematological, malignancy, urogenital, cardiovascular, digestive, or musculoskeletal disease:

  ① Thrombocytopenia ② Anemia ③ Neutropenia ④ Erythroderma ⑤ Latent or active tuberculosis

• Clinically significant systemic or topical skin infection at screening.
• Subjects who have taken systemic corticosteroids or immunosuppressive agents that can affect AD-related signs and symptoms within 4 weeks prior to the expected initial application date; subjects who have taken systemic anti-inflammatory or immunomodulatory drugs and systemic antibiotics that can affect AD-related signs and symptoms within 2 weeks prior to the expected initial application date; subjects who have received an UV light therapy to mitigate AD-related symptoms; subjects who are expected to take the above drugs or therapy within the study duration (however, the subject taking a corticosteroid inhaler or nasal spray with a stable dose for at least 3 months may participate in the clinical trial).
• Treatment with oral antihistamines or topical drugs (topical corticosteroid or calcineurin inhibitor, topical antihistamine, topical antimicrobial medication) that can affect AD-related signs and symptoms prior to the expected initial application date or within 5 life-lives, or subjects who are expected to take the above drugs within the study duration (however, the subject taking a nasal antihistamine spray for the treatment of allergic rhinitis may participate in the clinical trial).
• Subjects whose hair in the drug application site may be unavailable from 2 weeks prior to the expected initial application date to PSV.
• Subjects who have history of hypersensitivity (e.g., anaphylactic reaction or angioedema) to the drugs, including Janus kinase inhibitors and excipients, and other drugs (aspirin, penicillin antibiotics, macrolide antibiotics), or subjects who have history of clinically significant hypersensitivity.
• Suspected acute viral or bacterial infection within 2 weeks prior to the expected initial application date, or fever (body temperature in the tympanic membrane ≥ 38.0ºC) at the time of screening.

• The following clinically significant findings on 12-lead ECG at screening:

  • QTc > 450 ms
  • PR interval > 200 ms
  • QRS duration > 120 ms

• Any of the following abnormalities in clinical laboratory tests at the the time of screening:

  • Platelet or ANC level < 0.5 x lower limit of normal;
  • AST, ALT, ALP, γ-GTP, or total bilirubin level is ≥ 2 x upper limit of normal;
  • Serum creatinine level that is outside the reference range, or an eGFR < 60 mL/min/1.73m2 as determined by the CKD-EPI Equation;
  • Positive anti-HCV, HBs Ag, HIV Ag/Ab, Syphilis-RPR, or IGRA test.
• Subjects who received live vaccines within 3 months prior to the expected initial application date, or subjects who have a plan to receive live vaccines over a period from the informed consent to PSV.
• Subjects who have history of drug abuse, or who have a positive urine test for drugs of abuse.

• Subjects who have shown the following vital signs at screening when measured after at least 3-min rest:

  • Sitting systolic blood pressure ≥ 150 mmHg or ≤ 90 mmHg.
  • Sitting diastolic blood pressure ≥ 100 mmHg or ≤ 60 mmHg.
  • Sitting pulse rate ≤ 40 bpm or ≥ 100 bpm.
• Subjects who have taken prescription drugs or oriental medicines that may affect the characteristics of investigational product within 2 weeks prior to the expected initial application date, or subjects who have taken OTC drugs or vitamin preparations within 10 days prior to the expected initial application date, or subjects who are expected to take the above drugs over a period from the informed consent to PSV (however, if the drug is judged not to affect the PK profile of investigational product by the investigator, the subject may participate in the clinical trial.).
• Subjects who have participated in other clinical trials within 6 months prior to the expected initial application date (however, for the completion date of other clinical trials, the next date is calculated as 1 day on the basis of the last application date.).
• Subjects who have donated whole blood within 2 months prior to the expected initial application date or apheresis within 1 month, or received blood transfusion within 1 month prior to the expected initial application date, or subjects who cannot continuously abstain from blood donation over a period from the informed consent to PSV.

• Subjects who have history of regular alcohol consumption exceeding 21 units/week (1 unit = 10 g = 12.5 mL of pure alcohol) within 6 months prior to the expected initial application date, or subjects who cannot continuously abstain from alcohol consumption over a period from the informed consent to PSV.

  ☞The amount of alcohol (g) = alcohol consumption (mL) x alcohol content (%) x 0.8

• Subjects who have history of average use of 10 cigarettes daily within 3 months prior to the expected initial application date, and subjects who cannot cease smoking over a period from 24 hours prior to the expected initial application date to the last blood sampling point.
• Subjects who consumed grapefruit-containing food from 48 hours prior to the expected initial application date to PSV, or subjects who cannot avoid taking grapefruit-containing food during this period.
• Subjects who consumed caffeine-containing food (coffee, green tea, black tea, carbonated beverage, coffee-flavored milk, tonics, etc.) from 24 hours prior to the expected initial application date to the last blood sampling point, or subjects who cannot avoid drinking caffeine-containing food during this period.
• Subjects participating in regular strenuous exercise greater than daily physical activity from 48 hours prior to the expected initial application date to PSV, or subjects who cannot abstain from strenuous exercise during this period.
• Subjects or spouses (or partners) who have a plan for pregnancy or although unplanned pregnancy, are unable to use a highly effective method of contraception (e.g., use/implant of hormonal contraceptive or correctly placed intrauterine device, sterilization surgery (vasectomy, tubal ligation, etc.), barrier method (spermicide and condom, a concomitant use of contraceptive diaphragm, vaginal sponge or cervical cap)), over a period from the informed consent to 90 days after the last dose of investigational product.
• Subjects who are judged ineligible for the clinical study by the investigator due to reasons other than the above inclusion/exclusion criteria.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Triple

Number of Arms

11

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Part A-1(SAD1); IN-A002 Ointment 0.3% or Placebo Ointment, single dose	Drug: IN-A002 Ointment 0.3% or IN-A002 Placebo Ointment; Drug: IN-A002 Ointment 0.3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
Experimental: Part A-1(SAD2); IN-A002 Ointment 0.5% or Placebo Ointment, single dose	Drug: IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment; Drug: IN-A002 Ointment 0.5%, 10 g/1000 cm2, for 1 day Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2, for 1 day
Experimental: Part A-1(SAD3); IN-A002 Ointment 1% or Placebo Ointment, single dose	Drug: IN-A002 Ointment 1% or IN-A002 Placebo Ointment; Drug: IN-A002 Ointment 1%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
Experimental: Part A-1(SAD4); IN-A002 Ointment 3% or Placebo Ointment, single dose	Drug: IN-A002 Ointment 3% or IN-A002 Placebo Ointment; Drug: IN-A002 Ointment 3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
Experimental: Part A-1(SAD5); IN-A002 Ointment 5% or Placebo Ointment, single dose	Drug: IN-A002 Ointment 5% or IN-A002 Placebo Ointment; Drug: IN-A002 Ointment 5%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
Experimental: Part A-2(MAD1); IN-A002 Ointment 1% or Placebo Ointment, Twice daily (BID), multiple topical applications for 14 days	Drug: IN-A002 Ointment 1% or IN-A002 Placebo Ointment; Drug: IN-A002 Ointment 1%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
Experimental: Part A-2(MAD2); IN-A002 Ointment 3% or Placebo Ointment, Twice daily (BID), multiple topical applications for 14 days	Drug: IN-A002 Ointment 3% or IN-A002 Placebo Ointment; Drug: IN-A002 Ointment 3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
Experimental: Part A-2(MAD3); IN-A002 Ointment 5% or Placebo Ointment, Twice daily (BID), multiple topical applications for 14 days	Drug: IN-A002 Ointment 5% or IN-A002 Placebo Ointment; Drug: IN-A002 Ointment 5%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
Experimental: Part B(MAD1); IN-A002 Ointment 1%, Twice daily (BID), multiple topical applications for 28 days	Drug: IN-A002 Ointment 1%; Drug: IN-A002 Ointment 1%, 3 g/1000 cm2
Experimental: Part B(MAD2); IN-A002 Ointment 3%, Twice daily (BID), multiple topical applications for 28 days	Drug: IN-A002 Ointment 3%; Drug: IN-A002 Ointment 3%, 3 g/1000 cm2
Active Comparator: Part B; Part B(MAD1), (MAD2): Elidel Cream 1% (pimecrolimus), Twice daily (BID), multiple topical applications for 28 days	Drug: Elidel Cream 1% (pimecrolimus); Drug: Elidel Cream 1% (pimecrolimus), 3 g/1000 cm2

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse event	For all adverse events collected during the study, the investigator will evaluate serious adverse events, severity, or drug relationship.	Up to post study visit (Day 40)
Physical examination	Physical examination results will be classified as normal, not clinically significant, or clinically significant upon a judgment of the investigator after single/multiple dosing of topical IN-A002 Ointment.	Up to post study visit (Day 40)
Clinical Laboratory Test	Clinical laboratory test, the results will be classified as normal, not clinically significant, or clinically significant upon judgment of the investigator after single/multiple dosing of topical IN-A002 Ointment.	Up to post study visit (Day 40)
Topical Reaction Assessment	The numerical scores on the findings of skin reactions (erythema, papule, edema, bulla, blister) after single/multiple dosing of topical IN-A002 Ointment.	Predose(0h) at Day 1, Day 8, Day 15, and Day 22, Post-dose(0.5h) at Day 1, Day 8, Day 15, and Day 22, Day 28, Day 29(0h, 0.5h), PSV
NRS (Numerical Pain Rating Scale)	Each subject will subjectively evaluate the skin irritation intensity (pain) from the range of 1-10 using 'Numerical Rating Score (NRS)'.	Predose(0h) at Day 1, Day 8, Day 15, and Day 22, Post-dose(0.5h) at Day 1, Day 8, Day 15, and Day 22, Day 28, Day 29(0h, 0.5h), PSV
EASI score	Changes in EASI score from the baseline after treatment	Day 1, Day 8, Day 15, Day 22, Day 29
IGA score	Investigator Global Assessment (IGA) Changes in IGA score from the baseline after treatment	Day 1, Day 8, Day 15, Day 22, Day 29
Itch Questionnaire	Changes in Itch Questionnaire from the baseline after treatment; NRS for Pruritus; NRS for Sleep Disturbance; Duration of Itching	Day 1, Day 8, Day 15, Day 22, Day 29
Dermatology Life Quality Index (DLQI)	The DLQI is a 10-question questionnaire used to measure the impact of Atopic Dermatitis(AD) on the quality of life of an AD-affected person for the last week	Day 1, Day 8, Day 15, Day 22, Day 29

Collaborators and Investigators

• Sponsor: HK inno.N Corporation

Study record dates

Study Major Dates

• Study Start (Anticipated): February 13, 2023
• Primary Completion (Anticipated): February 25, 2023
• Study Completion (Anticipated): January 31, 2024

Study Registration Dates

• First Submitted: January 25, 2023
• First Submitted That Met QC Criteria: February 6, 2023
• First Posted (Actual): February 15, 2023

Study Record Updates

• Last Update Posted (Actual): February 15, 2023
• Last Update Submitted That Met QC Criteria: February 6, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Immune System Diseases; Hypersensitivity, Immediate; Genetic Diseases, Inborn; Skin Diseases, Genetic; Hypersensitivity; Skin Diseases, Eczematous; Dermatitis; Eczema; Dermatitis, Atopic; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Immunosuppressive Agents; Immunologic Factors; Dermatologic Agents; Phospholipase A2 Inhibitors; Calcineurin Inhibitors; Varespladib methyl; Pimecrolimus
• Other Study ID Numbers: IN_JSI_105

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No